Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024
07/05
Transcript : Intra-Cellular Therapies, Inc. - Special Call
16/04
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
16/04
AQ
Transcript : Intra-Cellular Therapies, Inc., Q4 2023 Earnings Call, Feb 22, 2024
22/02
Transcript : Intra-Cellular Therapies, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 08:15 AM
09/01
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
05/12
AQ
Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023
02/11
Transcript : Intra-Cellular Therapies, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:55 PM
12/23/12
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
11/23/11
AQ
Transcript : Intra-Cellular Therapies, Inc., Q2 2023 Earnings Call, Aug 03, 2023
03/23/03
Transcript : Intra-Cellular Therapies, Inc., Q1 2023 Earnings Call, May 04, 2023
04/23/04
Transcript : Intra-Cellular Therapies, Inc. - Special Call
28/23/28
Transcript : Intra-Cellular Therapies, Inc., Q4 2022 Earnings Call, Mar 01, 2023
01/23/01
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
08/22/08
AQ
Transcript : Intra-Cellular Therapies, Inc., Q3 2022 Earnings Call, Nov 03, 2022
03/22/03
Transcript : Intra-Cellular Therapies, Inc., Q2 2022 Earnings Call, Aug 09, 2022
09/22/09
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
13/22/13
AQ
Transcript : Intra-Cellular Therapies, Inc., Q1 2022 Earnings Call, May 10, 2022
10/22/10
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA (lumateperone) for Specific Patient Populations
26/22/26
AQ
Intra Cellular Therapies : Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations - Form 8-K
25/22/25
PU
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
25/22/25
AQ
Transcript : Intra-Cellular Therapies, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 07:30 AM
10/22/10
Transcript : Intra-Cellular Therapies, Inc., Q3 2021 Earnings Call, Nov 09, 2021
09/21/09
Transcript : Intra-Cellular Therapies, Inc. - Special Call
20/21/20
Transcript : Intra-Cellular Therapies, Inc., Q2 2021 Earnings Call, Aug 09, 2021
09/21/09
Transcript : Intra-Cellular Therapies, Inc., Q1 2021 Earnings Call, May 10, 2021
10/21/10
Transcript : Intra-Cellular Therapies, Inc. - Special Call
04/21/04
Transcript : Intra-Cellular Therapies, Inc., Q4 2020 Earnings Call, Feb 25, 2021
25/21/25
Transcript : Intra-Cellular Therapies, Inc., Q3 2020 Earnings Call, Nov 09, 2020
09/20/09
Intra-Cellular Therapies, Inc. Announces Executive Changes
02/20/02
CI
Intra Cellular Therapies : Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
02/20/02
AQ
INTRA-CELLULAR THERAPIES, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
02/20/02
AQ
Intra-Cellular Therapies, Inc. Announces Executive Changes
02/20/02
CI
Intra Cellular Therapies : Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
02/20/02
AQ
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
02/20/02
GL
Transcript : Intra-Cellular Therapies, Inc. - Special Call
09/20/09
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
27/19/27
GL
Transcript : Intra-Cellular Therapies, Inc., Q3 2018 Earnings Call, Nov 07, 2018
07/18/07
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results
07/18/07
GL
Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs
20/18/20
GL
Intra-Cellular Therapies Appoints Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs
20/18/20
CI